Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also revolutionized the treatment options for other B cell malignancies. Increasing evidence indicates that in addition to their...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2021-08-01
|
| Col·lecció: | Frontiers in Cell and Developmental Biology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fcell.2021.727531/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|